- Company
- Verquvo takes one step toward insurance coverage listing
- by Eo, Yun-Ho Mar 2, 2023 05:53am
- According to related industries, Bayer Korea's soluble guanylate cyclase (sGC) promoter Verquvo, which promotes the synthesis of intracellular cyclic monophosphate (cGMP), recently passed the HIRA. As a result, attention is focused on the future schedule of the Pharmaceutical Reimbursement Evaluation Committee. In December 2021, death due
- Company
- Daewoong botulinum toxin Nuceiva launched in Germany and Aus
- by Hwang, Jin-joon Mar 2, 2023 05:52am
- Daewoong Pharmaceutical announced on the 28th that its botulinum toxin 'Nuceiva' was officially launched in Germany and Austria through Evolus, a cosmetic indication partner in developed countries. Evolus, a partner for cosmetic indications in North America and the European Union, will be in charge of the distribution and marketing of Nuciva
- Company
- Jardiance vs Forxiga, competition in chronic kidney dz
- by Eo, Yun-Ho Feb 28, 2023 05:53am
- Competition outside the diabetes area for SGLT-2 inhibitors will further expand this year Following heart failure, this time it is kidney disease. Following AstraZeneca's Forxiga, Lilly and Boehringer Ingelheim's Jardiance also secured indications for chronic kidney disease, and competition is intensifying. In terms of speed, Forxiga is ahead
- Company
- Last year’s sales of Yuhan Leclaza were 16.1 billion won
- by Chon, Seung-Hyun Feb 28, 2023 05:52am
- Cumulative sales of 20 billion won in 1 year and 6 months after release. High growth prospects when promoted to first-line treatment. Yuhan Corporation's anti-cancer drug Leclaza is successfully settling in the domestic market. In the second year of its release, it posted sales of 16.1 billion won, breaking the record for annual sales of a new a
- Company
- Recordati Korean subsidiary was launched
- by Eo, Yun-Ho Feb 28, 2023 05:52am
- Italian pharmaceutical company Recordati Korean corporation was launched. Recordati Korea (Representative Lee Yeon-jae in Asia) announced on the 27th that it will officially launch its Korean branch and Asia-Pacific regional headquarters. The company is an Italian pharmaceutical company with a history of more than 90 years. Accordingly, the c
- Company
- Monthly sales of OTC Allegra rise 30% on average
- by Jung, Sae-Im Feb 28, 2023 05:52am
- Sales of Sanofi’s third-generation antihistamine drug ‘Allegra’ has risen 30% on average per month ever since it entered the over-the-counter (OTC) drug market. According to the market research institution IQUVA, sales of the OTC Allegra have risen 29% on average per month, ever since its release in March to the allergy season in Octo
- Company
- Will Tagrisso finally be reimbursed with public support?
- by Eo, Yun-Ho Feb 28, 2023 05:52am
- The D-day has finally been revealed. Will the lung cancer treatment ‘Tagrisso’ finally succeed in extending reimbursement to the first line? According to industry sources, AstraZeneca’s EGFR mutation-positive non-small cell lung cancer (NSCLC) treatment Tagrisso will be deliberated at the Health Insurance Review and Assessment Service
- Company
- Daiichi Sankyo Korea appoints Jeongtae Kim as new CEO
- by Eo, Yun-Ho Feb 27, 2023 05:57am
- Daiichi Sankyo Korea appointed Vice President Kim Jung-tae (49) as the new CEO. Daiichi Sankyo announced on the 20th that it will appoint Vice President Kim Jeong-tae as the new CEO and President Kim Dae-jung will retire on March 31. Accordingly, from April 1st, President Kim Dae-jung will support the company as an advisor, and new President
- Company
- Sales of 26-year-old Gemzar·Zyprexa show rebound
- by Kim, Jin-Gu Feb 27, 2023 05:57am
- The anticancer drug ‘Gemzar‘ and schizophrenia drug ‘Zyprexa' Boryung Pharmaceutical had acquired domestic sales and licensing lights of have enjoyed a rebound in sales. Sales of both drugs had been on a downfall prior to Boryung’s acquisition. Therefore, the analysis is that Boryung’s active portfolio expansion strategy and
- Company
- Will Luxturna will be deliberated by DREC for reimb?
- by Eo, Yun-Ho Feb 27, 2023 05:56am
- Industry attention is focused on whether progress will be made in discussions for the reimbursement of the one-shot retinal dystrophy treatment Luxturna. It was found that it is highly likely that Novartis Korea’s Inherited Retinal Dystrophy (IRD) treatment Luxturna (voretigene neparvovec) will be presented as an agenda for deliberation
